Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (Abstract 5).
Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—i...
Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...
Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract...
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).<...
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent resu...